By Associate Professor Megan Amanda Crumbaker

Journal articles

Crumbaker M; Khoja L; Joshua AM, 2017, 'AR signaling and the PI3K pathway in prostate cancer', Cancers, 9, pp. 34, http://dx.doi.org/10.3390/cancers9040034

Mersiades A; Crumbaker M; Gao B; Nagrial A; Hui R, 2017, 'P3.02c-033 Patterns of Progression and Management of Acquired Resistance to Anti-PD-1 Antibodies in Advanced Non-Small Cell Lung Cancer', Journal of Thoracic Oncology, 12, pp. S1293 - S1293, http://dx.doi.org/10.1016/j.jtho.2016.11.1828

Crumbaker M; Carlino M; Hui R; Mersiades A; Gurney H; Todd J; Gao B; Nagrial A, 2016, '471P Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC', Annals of Oncology, 27, pp. ix151 - ix151, http://dx.doi.org/10.1016/s0923-7534(21)00629-3

Crumbaker M; Carlino M; Hui R; Mersiades A; Gurney H; Todd J; Gao B; Nagrial A, 2016, '471P Baseline full blood count parameters as predictors of response to PD-1 inhibition in advanced NSCLC', Annals of Oncology, 27, http://dx.doi.org/10.1093/annonc/mdw594.035

Chan D; McLachlan JM; Crumbaker M; Marx GM, 2015, 'Pretreatment neutrophil/lymphocyte ratio (NLR) prior to steroids as a prognostic factor in metastatic castrate refractory prostate cancer (mCRPC) patients treated with taxanes.', JOURNAL OF CLINICAL ONCOLOGY, 33, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.273

McLachlan JM; Chan DL; Crumbaker MA; Marx GM, 2015, 'Neutrophil-lymphocyte ratio prior to steroids as a prognostic marker in men with metastatic castration-resistant prostate cancer', Cancer Treatment Communications, 4, pp. 81 - 85, http://dx.doi.org/10.1016/j.ctrc.2015.06.001

Back to profile page